Regeneron Says Improvement in Two POTS Measures Lasted 4 Weeks After One Dose of Baloncibart
Key Facts
Regeneron said on its October 30 earnings call that a single high dose of baloncibart improved heart rate and orthostatic symptom measures in patients with postural orthostatic tachycardia syndrome (POTS). The company added that the improvement lasted 4 weeks after the dose. That puts the duration of response among the key details the company reported about the clinical signal, without meaning the drug has become an approved treatment. Baloncibart is an experimental antibody targeting the NPR1 receptor, according to the company’s third-quarter earnings release. Regeneron had planned to present Phase 2 results at the American Autonomic Society meeting in November 2026.
The company described the improvement as covering the disease’s two main measures: heart rate and orthostatic symptoms. It said on the call that the improvement lasted four weeks after one dose, the duration it specified in its description of the results. The available information did not include details on the size of the change in each measure or a numerical comparison with the placebo group. The reported result therefore remains an early signal from a Phase 2 study, not evidence of efficacy established in a confirmatory trial. The company’s chief scientific officer said the improvement appeared linked to sustained restoration of intravascular blood volume.
A company official linked the disease to a chronic and pathological deficit in intravascular blood volume, and said the improvement after the high dose appeared connected to restoration of that volume. This explanation presents Regeneron’s view of the potential mechanism behind the changes in the two measures, rather than an independent finding beyond its description of the data. According to the company, current options include salt and fluid administration, but they provide only short-term relief. It added that off-label treatments are generally unsatisfactory and that there are no treatments approved by the U.S. Food and Drug Administration for the syndrome. Baloncibart itself remains an experimental drug at this stage of development.
The National Heart, Lung, and Blood Institute describes POTS as an excessive increase in heart rate and other symptoms that worsen when standing or sitting. Symptoms listed by the institute include dizziness, shortness of breath, chest pain and palpitations. There are no precise data on how common the condition is, but the institute’s estimate published in 2019 puts it between 0.2% and 1% of the U.S. population. The institute also says there is no cure or standard treatment for the syndrome, and that available options focus on symptoms rather than the underlying disease. This background explains the company’s interest in the hypothesis of targeting intravascular blood volume, without resolving whether the approach will deliver a sustained therapeutic benefit.
Regeneron plans to start a Phase 3 study in the first half of 2027, subject to regulatory feedback. This is the next step the company has announced in developing baloncibart to treat POTS. The planned timing follows its announcement that it intended to present Phase 2 results during November 2026. In the stock market, Regeneron shares closed at $959.41 on November 11, according to EL7 data. That closing price comes after the October 30 earnings call, not before it; the evidence does not link the closing price to the trial results announcement or establish that the stock moved in response to it.